|
Final Guidance Optimizes Genotoxicity Tests, Should Improve Risk Characterization
The FDA has revised its guidance on testing a new drug’s genotoxicity to help drugmakers optimize the standard genetic toxicology battery and better predict potential human risks.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives